001     279306
005     20210129221032.0
024 7 _ |a 10.1021/acs.jpcb.5b04822
|2 doi
024 7 _ |a 1089-5647
|2 ISSN
024 7 _ |a 1520-5207
|2 ISSN
024 7 _ |a 1520-6106
|2 ISSN
024 7 _ |a WOS:000359031400022
|2 WOS
024 7 _ |a altmetric:4240936
|2 altmetric
024 7 _ |a pmid:26130191
|2 pmid
037 _ _ |a FZJ-2015-07321
082 _ _ |a 530
100 1 _ |a Carballo-Pacheco, Martín
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Oligomer Formation of Toxic and Functional Amyloid Peptides Studied with Atomistic Simulations
260 _ _ |a Washington, DC
|c 2015
|b Soc.
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1449731619_5827
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
520 _ _ |a Amyloids are associated with diseases, including Alzheimer’s, as well as functional roles such as storage of peptide hormones. It is still unclear what differences exist between aberrant and functional amyloids. However, it is known that soluble oligomers formed during amyloid aggregation are more toxic than the final fibrils. Here, we perform molecular dynamics simulations to study the aggregation of the amyloid-β peptide Aβ25–35, associated with Alzheimer’s disease, and two functional amyloid-forming tachykinin peptides: kassinin and neuromedin K. Although the three peptides have similar primary sequences, tachykinin peptides, in contrast to Aβ25–35, form nontoxic amyloids. Our simulations reveal that the charge of the C-terminus is essential to controlling the aggregation process. In particular, when the kassinin C-terminus is not amidated, the aggregation kinetics decreases considerably. In addition, we observe that the monomeric peptides in extended conformations aggregate faster than those in collapsed hairpin-like conformations.
536 _ _ |a 553 - Physical Basis of Diseases (POF3-553)
|0 G:(DE-HGF)POF3-553
|c POF3-553
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Ismail, Ahmed E.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Strodel, Birgit
|0 P:(DE-Juel1)132024
|b 2
|e Corresponding author
|u fzj
773 _ _ |a 10.1021/acs.jpcb.5b04822
|g Vol. 119, no. 30, p. 9696 - 9705
|0 PERI:(DE-600)2006039-7
|n 30
|p 9696 - 9705
|t The @journal of physical chemistry / B
|v 119
|y 2015
|x 1520-5207
856 4 _ |u http://pubs.acs.org/doi/abs/10.1021/acs.jpcb.5b04822
856 4 _ |u https://juser.fz-juelich.de/record/279306/files/Oligomer%20Formation%20of%20Toxic%20and%20Functional%20Amyloid%20Peptides%20Studied%20with%20Atomistic%20Simulations.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/279306/files/Oligomer%20Formation%20of%20Toxic%20and%20Functional%20Amyloid%20Peptides%20Studied%20with%20Atomistic%20Simulations.gif?subformat=icon
|x icon
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/279306/files/Oligomer%20Formation%20of%20Toxic%20and%20Functional%20Amyloid%20Peptides%20Studied%20with%20Atomistic%20Simulations.jpg?subformat=icon-1440
|x icon-1440
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/279306/files/Oligomer%20Formation%20of%20Toxic%20and%20Functional%20Amyloid%20Peptides%20Studied%20with%20Atomistic%20Simulations.jpg?subformat=icon-180
|x icon-180
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/279306/files/Oligomer%20Formation%20of%20Toxic%20and%20Functional%20Amyloid%20Peptides%20Studied%20with%20Atomistic%20Simulations.jpg?subformat=icon-640
|x icon-640
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/279306/files/Oligomer%20Formation%20of%20Toxic%20and%20Functional%20Amyloid%20Peptides%20Studied%20with%20Atomistic%20Simulations.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:279306
|p VDB
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 2
|6 P:(DE-Juel1)132024
913 1 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-553
|2 G:(DE-HGF)POF3-500
|v Physical Basis of Diseases
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J PHYS CHEM B : 2014
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)IBI-7-20200312


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21